Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

D-007

Supelco

Desmethyldoxepin solution

cis/trans, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C18H19NO
Numero CAS:
1225-56-5
Peso molecolare:
265.35
Numero MDL:
MFCD16879065
Codice UNSPSC:
41116107
ID PubChem:
329798578
NACRES:
NA.24

Grado

certified reference material

Forma fisica

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

CNCC/C=C1C2=C(C=CC=C2)COC3=C/1C=CC=C3

InChI

1S/C18H19NO/c1-19-12-6-10-16-15-8-3-2-7-14(15)13-20-18-11-5-4-9-17(16)18/h2-5,7-11,19H,6,12-13H2,1H3/b16-10-
HVKCEFHNSNZIHO-YBEGLDIGSA-N

Descrizione generale

Desmethyldoxpein is the primary urinary metabolite of doxepin, a tricyclic antidepressant used for the treatment of sleep maintenance and sold under trade names such as Silenor® and Aponal. This analytical reference standard is suited for use in LC/MS or GC/MS methods for urine drug testing, clinical toxicology, and forensic analysis applications.

Applicazioni

Desmethyldoxepin solution may be used as an internal standard in the high performance liquid chromatographic (HPLC) determination of bupivacaine in samples of human serum.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Silenor is a registered trademark of Somaxon Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

High-performance liquid chromatographic determination of bupivacaine in human serum
Lindberg.P.L.R
Journal of Chromatography. B, Biomedical Sciences and Applications, 309, 369-374 (1984)
Robert Schomburg et al.
Journal of neural transmission (Vienna, Austria : 1996), 118(4), 641-645 (2011-02-26)
Doxepin--like other antidepressant drugs (ADs)--shows a variable antidepressant effect in clinical practice. The cause for this variability is as yet unclear; however, pharmacokinetic factors such as the variable permeability of doxepin into the cerebrospinal fluid (CSF), may contribute to the
K K Midha et al.
European journal of clinical pharmacology, 42(5), 539-544 (1992-01-01)
Commercial preparations of the tricyclic anti-depressant doxepin contain 15% of the more active cis-doxepin and 85% of the trans-isomer. The single dose pharmacokinetics of doxepin and its major metabolite N-desmethyldoxepin were examined in 30 healthy young men. Results for total
Heinz-Werner Hagedorn et al.
Journal of pharmaceutical and biomedical analysis, 29(1-2), 317-323 (2002-06-14)
Due to its tranquilizing properties, the tricyclic antidepressant doxepin may be misused as a doping agent in competition horses. Therefore, efficient analytical procedures are required to detect this drug in samples submitted for doping control. To screen for parent doxepin
M Meyer-Barner et al.
European journal of clinical pharmacology, 58(4), 253-257 (2002-07-24)
Little information on the population pharmacokinetics of the tricyclic antidepressant doxepine and its pharmacologically active metabolite desmethyldoxepine is available. However, a more individualised drug therapy may be feasible if the influence of various patient characteristics on plasma concentration was known.
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.